Malignant pleural effusion: Tumor-host interactions unleashed

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 6, 2012, Pages 487-492

  Stathopoulos, Georgios T ^a   Kalomenidis, Ioannis ^b  

^a UNIVERSITY OF PATRAS   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Adenocarcinoma; Angiogenesis; Exudate; Inflammation; Vascular permeability

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; BETA INTERFERON; CEDIRANIB; EPIDERMAL GROWTH FACTOR RECEPTOR; FOLIC ACID ANTAGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSTIMULATING AGENT; INTERLEUKIN 5; INTERLEUKIN 6; MACROPHAGE DERIVED CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ZOLEDRONIC ACID;

APOPTOSIS; CANCER PATIENT; CELL FUNCTION; COLON ADENOCARCINOMA; DISEASE COURSE; DISEASE MODEL; EXTRAVASATION; GENE TRANSFER; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENCE; LUNG ADENOCARCINOMA; MALIGNANT PLEURAL EFFUSION; MESOTHELIOMA; MULTICENTER STUDY (TOPIC); NONHUMAN; OBSERVATIONAL STUDY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA CAVITY; PLEURA EFFUSION; PLEURA FLUID; PLEURA MESOTHELIOMA; PLEURA TUMOR; PRIORITY JOURNAL; REVIEW; TUMOR CELL; VASCULARIZATION;

ANIMALS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 84866396396     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201203-0465PP     Document Type: Review

References (49)

1. Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ; BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010;65:ii32-ii40.
2. American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000;162:1987-2001.
3. Lee YCG, Light RW. Management of malignant pleural effusions. Respirology 2004;9:148-156.
4. Kalomenidis I. Beyond talc pleurodesis: do we really need new methods? Respirology 2011;73:171-175.
5. Burgers JA, Kunst PW, Koolen MG, Willems LN, Burgers JS, van den Heuvel M. Pleural drainage and pleurodesis: implementation of guidelines in four hospitals. Eur Respir J 2008;32:1321-1327.
6. Shan SA. Pleural diseases related to metastatic malignancies. Eur Respir J 1997;10:1907-1913.
7. Maker AV, Nguyen DM. Active malignant pleural effusion captured through the thoracoscope. Ann Thorac Surg 2005;80:1941.
8. Sakr L, Maldonado F, Greillier L, Dutau H, Loundou A, Astoul P. Thoracoscopic assessment of pleural tumor burden in patients with malignant pleural effusion: prognostic and therapeutic implications. J Thorac Oncol 2011;6:592-597.
9. Light RW, Hamm H. Malignant pleural effusion: would the real cause please stand up? Eur Respir J 1997;10:1701-1702.
10. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Fidler IJ. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol 2000;157:1893-1903.
11. Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 2000;6:957-965.
12. Ishii H, Yazawa T, Sato H, Suzuki T, Ikeda M, Hayashi Y, Takanashi Y, Kitamura H. Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs). Lung Cancer 2004;45:325-337.
13. Pichelmayer O, Gruenberger B, Zielinski C, Raderer M. Bevacizumab is active in malignant effusion. Ann Oncol 2006;17:1853.
14. Stathopoulos GT, Zhu Z, Everhart MB, Kalomenidis I, Lawson WE, Bilaceroglu S, Peterson TE, Mitchell D, Yull FE, Light RW, et al. Nuclear factor-kB affects tumor progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol 2006;34:142-150.
15. Stathopoulos GT, Sherrill TP, Karabela SP, Goleniewska K, Kalomenidis I, Roussos C, Fingleton B, Yull FE, Peebles RS Jr, Blackwell TS. Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion. Am J Respir Crit Care Med 2010;182:1273-1281.
16. Stathopoulos GT, Kollintza A, Moschos C, Psallidas I, Sherrill TP, Pitsinos EN, Vassiliou S, Karatza M, Papiris SA, Graf D, et al. Tumor necrosis factor-a promotes malignant pleural effusion. Cancer Res 2007;67:9825-9834.
17. Stathopoulos GT, Psallidas I, Moschos C, Moustaki A, Kollintza A, Karabela S, Porfyridis I, Vassiliou S, Karatza M, Zhou Z, et al. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J Natl Cancer Inst 2008;100:1464-1476.
18. Cui R, Takahashi F, Ohashi R, Yoshioka M, Gu T, Tajima K, Unnoura T, Iwakami S, Hirama M, Ishiwata T, et al. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer. Lung Cancer 2009;63:368-374.
19. Psallidas I, Stathopoulos GT, Maniatis NA, Magkouta S, Moschos C, Karabela SP, Kollintza A, Simoes DC, Kardara M, Vassiliou S, et al. Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion. Oncogene (In press)
20. Moschos C, Psallidas I, Kollintza A, Karabela S, Papapetropoulos A, Papiris S, Light RW, Roussos C, Stathopoulos GT, Kalomenidis I. The angiopoietin/Tie2 axis mediates malignant pleural effusion formation. Neoplasia 2009;11:298-304.
21. Nasreen N, Mohammed KA, Brown S, Su Y, Sriram PS, Moudgil B, Loddenkemper R, Antony VB. Talc mediates angiostasis in malignant pleural effusions via endostatin induction. Eur Respir J 2007;29:761-769.
22. Fang F, Chen P, Wu X, Yang L, Yang X, Xi ZX, Zhou BW, Zhou XK, Qian ZY, Xiao B, et al. Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion. J Cancer Res Clin Oncol 2009;135:1149-1157.
23. Yeh H-H, Lai W-W, Chen HHW, Liu H-S, Su W-C. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 2006;25:4300-4309.
24. Wu SG, Gow CH, Yu CJ, Chang YL, Yang CH, Hsu YC, Shih JY, Lee YC, Yang PC. Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur Respir J 2008;32:924-930.
25. Han HS, Eom DW, Kim JH, Kim KH, Shin HM, An JY, Lee KM, Choe KH, Lee KH, Kim ST, et al. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. Clin Lung Cancer 2011;12:380-386.
26. Stathopoulos GT, Moschos C, Loutrari H, Kollintza A, Psallidas I, Karabela S, Magkouta S, Papiris SA, Roussos C, Kalomenidis I. Zoledronic acid is effective against experimental malignant pleural effusion. Am J Respir Crit Care Med 2008;178:50-59.
27. Gary Lee YC, Melkerneker D, Thompson PJ, Light RW, Lane KB. Transforming growth factor beta induces vascular endothelial growth factor elaboration from pleural mesothelial cells in vivo and in vitro. Am J Respir Crit Care Med 2002;165:88-94.
28. Nasreen N, Mohammed KA, Sanders K, Hardwick J, Van Horn RD, Sriram PS, Ramirez-Icaza C, Hage C, Antony VB. Pleural mesothelial cell (PMC) defense mechanisms against malignancy. Oncol Res 2003;14:155-161.
29. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009;16:183-194.
30. Noppen M, De Waele M, Li R, Gucht KV, D'Haese J, Gerlo E, Vincken W. Volume and cellular content of normal pleural fluid in humans examined by pleural lavage. Am J Respir Crit Care Med 2000;162:1023-1026.
31. Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Hegmans JP, Aerts JG. Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. Br J Cancer 2010;103:629-641.
32. Chen YQ, Shi HZ, Qin XJ, Mo WN, Liang XD, Huang ZX, Yang HB, Wu C. CD4+CD25+ regulatory T lymphocytes in malignant pleural effusion. Am J Respir Crit Care Med 2005;172:1434-1439.
33. Qin XJ, Shi HZ, Deng JM, Liang QL, Jiang J, Ye ZJ. CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion. Clin Cancer Res 2009;15:2231-2237.
34. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
35. Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H, Balkwill FR. Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cancer Ther 2007;6:1993-2002.
36. Lane D, Robert V, Grondin R, Rancourt C, Piché A. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Int J Cancer 2007;121:1227-1237.
37. Lane D, Goncharenko-Khaider N, Rancourt C, Piché A. Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene 2010;29:3519-3531.
38. Moschos C, Psallidas I, Cottin T, Kollintza A, Papiris S, Roussos C, Stathopoulos GT, Giannis A, Kalomenidis I. A sulindac analogue is effective against malignant pleural effusion in mice. Lung Cancer 2011;73:171-175.
39. Psallidas I, Karabela SP, Moschos C, Sherrill TP, Kollintza A, Magkouta S, Theodoropoulou P, Roussos C, Blackwell TS, Kalomenidis I, et al. Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study. Mol Cancer 2010;9:56.
40. Cerniglia GJ, Pore N, Tsai JH, Schultz S, Mick R, Choe R, Xing X, Durduran T, Yodh AG, Evans SM, et al. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS ONE 2009;4:e6539.
41. Stathopoulos GT. Translational advances in pleural malignancies. Respirology 2011;16:53-63.
42. Sterman DH, Recio A, Haas AR, Vachani A, Katz SI, Gillespie CT, Cheng G, Sun J, Moon E, Pereira L, et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther 2010;18:852-860.
43. Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008;5:136-147.
44. Jongsma J, van Montfort E, Vooijs M, Zevenhoven J, Krimpenfort P, van der Valk M, van de Vijver M, Berns A. A conditional model of malignant mesothelioma. Cancer Cell 2008;13:261-271.
45. Moschos C, Porfiridis I, Psallidas I, Kollintza A, Stathopoulos GT, Papiris SA, Roussos C, Kalomenidis I. Osteopontin is upregulated in malignant and inflammatory pleural effusions. Respirology 2009;14:716-722.
46. Hsu IL, Su WC, Yan JJ, Chang JM, Lai WW. Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control. Lung Cancer 2009;65:371-376.
47. Grigoriu BD, Chahine B, Vachani A, Gey T, Conti M, Sterman DH, Marchandise G, Porte H, Albelda SM, Scherpereel A. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am J Respir Crit Care Med 2009;179:950-954.
48. Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007;25:2741-2746.
49. Basak SK, Veena MS, Oh S, Huang G, Srivatsan E, Huang M, Sharma S, Batra RK. The malignant pleural effusion as a model to investigate intratumoral heterogeneity in lung cancer. PLoS ONE 2009;4:e5884.